Why the study?
Does pioglitazone improve LV remodeling and function in mice with post-MI heart failure?
Does pioglitazone improve LV remodeling and function in mice with post-MI heart failure?
Pioglitazone shows promise in attenuating LV remodeling and improving function in a preclinical model of post-MI heart failure.
Does not support clinical use in post-MI HF; leaves open translation from murine models.
Pioglitazone improved LV remodeling and function in mice with post-MI heart failure. This effect was associated with an attenuated LV expression of inflammatory cytokines and chemokines. Peroxisome proliferator-activated receptor-gamma ligands have promise as preventive and therapeutic agents against heart failure.
No takes yet. Share an insight, caveat, or question.
Shiomi et al. (2002) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: